Cannabis and ms
Browse the latest research linking medical marijuana / medicinal cannabis and ms.
Medical cannabis has been shown superior to placebo in reducing pain and spasticity in MS patients in human placeo trials.
See also: pain  spasticity 
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
cannabis ms in humans via article In the cloud of cannabis: Caring for people with multiple sclerosis who use cannabis for symptom control 2019
Research to-date suggests a large proportion of people living with MS are using cannabis as a way to self-manage symptoms, and, if not, believe that there are potential benefits in using this drug
cannabis ms,spasticity in humans via survey (n=29) Cannabis Use in People with Multiple Sclerosis and Self-Reported Spasticity Apr 2019
Positive  All subjects reported cannabis being somewhat or very helpful for pain and 78% (7/9) reported similar benefit for spasticity.
cannabis ms,spasticity,pain in humans via placebo trial (n=30/37) Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial Jul 2012
Ingestion Method: inhaled 0.8g cigarette, 4% THC
Positive  Using an objective measure, we saw a beneficial effect of inhaled cannabis on spasticity among patients receiving insufficient relief from traditional treatments. Although generally well-tolerated, smoking cannabis had acute cognitive effects.
cannabis ms,spasticity in humans via placebo trial (n=37/50) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Aug 2004
Ingestion Method: oral 2.5mg THC/0.9mg CBD
Positive  A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs.
THC,CBD ms,neuropathy in humans via placebo trial (n=64) Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Sep 2007
Ingestion Method: Sativex THC/CBD (27 mg/mL: 25 mg/mL) spray
Positive  THC/CBD was effective, with no evidence of tolerance, in these select patients with CNP and MS who completed approximately 2 years of treatment (n = 28).
CBD ms in mice via experiment Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. Feb 2019
Ingestion Method: CBD-rich, ?9-THC low Cannabis indica subspecies (Avidekel)
Our data show that CBD and purified Avidekel extracts are as efficient as Copaxone to alleviate the symptoms of proteolipid protein (PLP)-induced EAE in SJL/J mice. No synergistic effect was observed by combining CBD or Avidekel extracts with Copaxone. Our data support the use of Avidekel extracts in the treatment of MS symptoms.
cannabis ms in humans via survey (n=2244/3606) Illegal cannabis use is common among Danes with multiple sclerosis May 2019
Positive  This study shows that illegal cannabis use is common among Danes with MS as only 21% of the current cannabis users received prescribed cannabis-based medicine. Current cannabis users reported high efficacy in relieving pain, spasticity and sleep disturbances. In addition, only mild to moderate severity of adverse effects were reported
cannabinoids diabetes,ra,ms via review Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand? May 2019
Action Pathway: CB1,CB2
Thus, in this review, we summarize the mechanisms by which CBRs interact with the autoimmune environment and the potential to suppress the development and activation of autoreactive cells. Finally, we highlight how the modulation of CB1R and CB2R is advantageous in the treatment of autoimmune diseases, including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM) and rheumatoid arthritis (RA).